ArticleContemporary clinical trials communications2025

Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial.

Jorge Diaz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.